Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]Ga-FAPI-46 PET in pancreatobiliary cancers (PANSCAN-1)
2024-516486-36-00Phase 3Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, open-label trial of gallium-68 chloride in pancreatic cancer (PC), cholangiocarcinoma (CCA) and pancreatic adenocarcinoma (PDAC) (3 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Part A: Optimal kinetic model and simplified measurement for [68Ga]Ga-FAPI-46, Part B: Test–retest variability of preferred simplified quantification method and 2 more. Planned start Sep 2024; status: authorised.
02
Drugs
gallium-68 chloride
03
Conditions
pancreatic cancer (PC)cholangiocarcinoma (CCA)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-516486-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516486-36-00.